Eli Lilly originally gained US approval for teriparatide (Forteo) in 2002 and European approval in 2003, based on results from a phase 3 study. The originator teriparatide patent expired in 2019, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback